Cecilia Pessoa Gingerich

From 2000 to 2016, the proportion of organ donors who died of drug intoxication increased from 1.2% to 13.7% in the US.

The oral dual inhibitor is intended to work alongside insulin therapy to improve blood sugar control in adults with type 1 diabetes.

This is the fifth indication approved for Amgen’s Prolia (denosumab), which targets RANK Ligand, an essential regulator of osteoclasts.

FlowTriever is the first thrombectomy device cleared for the treatment of pulmonary embolism.

Cerenovus’ mechanical thrombectomy device is indicated for the removal of blood clots in the 8 hours following ischemic stroke.

Lokelma is approved for the treatment of hyperkalemia, which is characterized by elevated potassium levels often associated with cardiovascular, renal, and metabolic diseases.

Despite the challenges of studying the condition, researchers showed that galcanezumab significantly reduced weekly cluster headache attacks compared to placebo.

AstraZeneca announced that the first of its 2 phase 3 trials of benralizumab for severe COPD failed to meet its primary efficacy endpoint.

The Spectrum IQ system is designed to integrate with bi-directional EMRs and incorporates the First Databank evidence-based library of IV medications.

Physicians who received non-research opioid-related payments from the pharmaceutical industry in 2014 had 9.3% more opioid claims in 2015 than physicians who did not.

Patients treated with dabigatran following myocardial injury after noncardiac surgery were 20% less likely to die of a cardiovascular cause.

Researchers found that biased language affected a physician’s attitude toward a patient as well as the aggressiveness of their pain management choices.

The HeartLight Excalibur Balloon, designed for the treatment of paroxysmal atrial fibrillation, is ultra-compliant and can be resized in real-time.

EpiFinder, a mobile health application, predicted either an epilepsy syndrome or alternative diagnosis with 86.8% accuracy.

The Advisor™ HD Grid Mapping Catheter, Sensor Enabled™ provides physicians with a detailed map of cardiac tissue to allow for more precise ablation therapy.

Children receiving AVXS-101 have shown such improvement that researchers are calling for an update to the CHOP-INTEND scale used to track their progress.

Patients who had previously failed ≥2 preventative migraine treatments were effectively treated with galcanezumab, especially when compared to placebo.

Researchers found that 100U of incobotulinumtoxinA significantly reduced unstimulated salivary flow rate during the 16-week trial and through the 48-week extension.

The American Academy of Neurology has issued 30 recommendations for clinicians regarding disease-modifying therapies for multiple sclerosis.

Depressed mothers provided less support to their child, influencing the child’s IQ. The reverse effect, where children’s IQ affected maternal depression, was also seen.

Among patients with MS who began ocrelizumab treatment in the open-label extension, MRI lesion activity was almost completely suppressed.

Trial results on the recently FDA-approved gammaCore device will be presented at the American Academy of Neurology (AAN) annual meeting.

A wrist-worn neuromodulation device delivers a nerve stimulation pattern tailored to the patient’s tremor.

Study results show 30.3% of difficult to treat patients taking erenumab saw at least a 50% reduction in monthly migraine days.

Burosumab is the first FDA approved treatment for this rare, hereditary disorder that affects 3000 children and 12,000 adults in the US.

An Alzheimer’s diagnosis may cause fear, but the broad spectrum of cognitive impairment means some physicians can continue to practice despite the disease.

Mobile apps have a high potential for improving treatment adherence, but rigorous testing is still needed to determine efficacy.

Results indicated that canagliflozin provided renal benefits for T2D patients with preserved or reduced kidney function.

Investigators noted promising results for secondary outcomes but demonstrated no difference for the primary outcome of reducing hospital visits due to self-harm.

The contact lenses, which darken when exposed to strong UV light, were cleared through the 501(k) pathway.